Sitagliptin
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Sitagliptin
Sitagliptin: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Sitagliptin, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 3 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| diabetes mellitus, type 2 | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| diabetes mellitus |
| type 2 diabetes mellitus |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 13871C | Sitagliptin Sandoz Pharma | Tablet 100 mg | Valid |
Safety Considerations
Safety information was drawn from knowledge-graph contraindication edges and drug interaction data, not from product label text.
- Knowledge-graph contraindication signals (disease associations, not label text): pancreatitis, kidney disease, liver disease, gallbladder disease, adrenocortical insufficiency/Addison disease, infectious disease, thymus gland disease, and a broad group of pituitary hormone deficiency and hypogonadotropic hypogonadism conditions.
- Drug interactions: 100 interactions were identified. Those shown in the data are mostly Moderate, with a few Minor. Moderate examples include:
- sympathomimetics and bronchodilators (phenylephrine, pseudoephedrine, epinephrine, salbutamol, formoterol)
- corticosteroids (hydrocortisone, triamcinolone)
- hormonal agents (estradiol, levonorgestrel, norethisterone, desogestrel)
- others (hydrochlorothiazide, acetazolamide, benazepril, aripiprazole, alpelisib, apalutamide, ethanol)
Minor examples are topical hydrocortisone and topical alclometasone.
- Pancreatitis: a case report in the compiled literature (PMID 32337116) describes sitagliptin-induced pancreatitis after long-term use. This is relevant to any new use.
Please also refer to the TGA-approved Product Information (PI) for full warnings and contraindications, as label-based safety data were not available for this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.